News and Announcements
Proteomics Commences Therapeutic Drug Discovery Program
- Published March 23, 2016 1:52PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
23rd Marc h 2016, ASX Announcement
Highlights:
- PILL to utilise its proprietary disruptive technology platform to assess potential new painkilling and antibiotic drug compounds.
- Therapeutic Drug Discovery is one of PILL’s core business areas and is a major growth market – peptide therapeutics market estimated value is $17b.
- Program is low cost and has potential deliver major end returns.
- PILL’s drug discovery process delivers a significant reduction in discovery timeline and a substantial cost advantage relative to traditional drug delivery
Life science company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce that it has commenced a Therapeutic Drug Discovery program utilising its proprietary proteomics-based technology platform.
The Company is specifically targeting the discovery of new analgesic (painkilling) and antibiotics compounds and will test 50 – 100 venoms in the program. The program is low cost to PILL, with no additional costs incurred apart from sourcing the venom samples, and has the potential deliver highly significant end returns.
To view the full article please click on the button below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
